Neuroendocrine Differentiation in Prostate Cancer: Implications for New Treatment Modalities

This publication has 61 references indexed in Scilit:

• Role of ^99mTc-Bombesin Scan in Diagnosis and Staging of Prostate Cancer
  Cancer Biotherapy & Radiopharmaceuticals, 2004
• Regulation of interleukin‐6‐mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells
  The Prostate, 2004
• Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma
  The Prostate, 2002
• Interleukin-6- and Cyclic AMP-Mediated Signaling Potentiates Neuroendocrine Differentiation of LNCaP Prostate Tumor Cells
  Molecular and Cellular Biology, 2001
• Somatostatin and Its Receptor Family
  Frontiers in Neuroendocrinology, 1999
• Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin
  Oncogene, 1999
• Cancer statistics, 1998
  CA: A Cancer Journal for Clinicians, 1998
• Liarozole (R75251) in hormone-resistant prostate cancer patients
  The Prostate, 1997
• Androgen receptor alterations in prostatic carcinoma
  The Prostate, 1994
• A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgens
  Biochemical and Biophysical Research Communications, 1990